Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Conditions
Non-small Cell Lung Cancer (NSCLC) · Colorectal Cancer (CRC) · Pancreatic Ductal Adenocarcinoma (PDAC) · Advanced Solid Tumors
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
UC Irvine/Chao Family Comprehensive Cancer Center, Orange, California, United States
UCLA, Santa Monica, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
Johns Hopkins University, Baltimore, Maryland, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Columbia University, New York, New York, United States
Christ Hospital Cancer Center, Cincinnati, Ohio, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
University of Texas at Austin, Austin, Texas, United States
Mary Crowley Cancer Research, Dallas, Texas, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Next Oncology, San Antonio, Texas, United States
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Next Oncology Virginia, Fairfax, Virginia, United States
Study leads
Revolution Medicines, Inc.
Study Director
Revolution Medicines, Inc.